Topic: non-small cell lung cancer
Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict
AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.
Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.
The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.
Investors panicked in October when Bristol-Myers Squibb said a request for more data from a key lung cancer trial had pushed back an FDA decision.
For the fourth quarter, analysts expect Keytruda to maintain its lead over Opdivo. But it’s Opdivo that could surprise Wall Street, one analyst says.
When 2018 began, there was still plenty of uncertainty for I-O drugmakers in lung cancer. But as 2019 nears, Merck's dominance looks pretty clear.
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.
Hutchison China MediTech’s Elunate, which was the first China-made drug to win a major oncology approval, has flopped in a key lung cancer trial.